VPAS

Views & Analysis

What can Linux and Mozilla teach ICER about how to do drug value assessments?

What’s affordable anyway? The future of NHS drug spending

The single biggest monetary difference that can be made to the successor to the UK’s 2019 Voluntary Scheme for branded medicines pricing and access (VPAS) is to address the question of how

Views & Analysis

Progress two years in and opportunities to improve over next three years

VPAS: Progress two years in and opportunities to improve ove...

In the final instalment of our series reviewing the

Views & Analysis

Achievement so far on objectives for the economy and innovation

VPAS: Achievement so far on objectives for the economy and i...

In the third part of this series taking stock of

Views & Analysis

Achievement-so-far-on-objective-on-affordability

VPAS: Achievements so far on affordability

In the second part of this series taking stock of

Views & Analysis

VPAS: Achievement so far on objectives for patients

The UK has a voluntary agreement that was struck by the government and NHS England (now referred to as NHSE&I) with the Association of the British Pharmaceutical Industry (ABPI) in 2018

Views & Analysis